Innovent Biologics rises 10% after striking up to $10.5 billion oncology deal with Pfizer
Chinese biotech Innovent Biologics rose as much as 10% on Hong Kong's exchange after signing a strategic global licensing and collaboration agreement with US pharma giant Pfizer. The deal covers oncology medicines and includes upfront and milestone payments worth up to $10.5 billion.
According to CNBC, Innovent Biologics rose as much as 10% on the Hong Kong exchange after announcing a global licensing and collaboration deal with Pfizer. The main programme covers several targeted-therapy candidates used in cancer treatment. Pfizer payments could reach a total of $10.5 billion, combining upfront amounts with development and commercial milestones.
China's pharmaceutical sector has stood out over the past two years through licensing deals signed with major global drug companies, and analysts say the trend signals a maturing Chinese R&D ecosystem. Innovent chief executive Yongjun Liu said Pfizer's global commercialisation network would speed patient access. On the Pfizer side, executives stressed that the deal strengthens the oncology portfolio and helps balance R&D costs.
Clinical approvals and regulatory milestones will be decisive for the contract's ultimate value. The agreement is expected to advance in parallel with reviews at the US FDA, the European EMA and China's National Medical Products Administration. This article reports facts as published; it does not constitute investment or medical advice.
More from North America
US general meets Cuban military officials at Guantanamo perimeter
General Francis Donovan met Cuban military officials at the edge of the US Naval Base at Guantanamo Bay, CNBC reported. The contact comes amid growing concerns of a possible US military action against the island and warrants careful framing of intent on both sides.
UAE says OPEC exit was a strategic economic move, not political
The United Arab Emirates said its decision to leave OPEC was a strategic economic choice rather than a political one. Officials told CNBC the move lets the country deploy spare production capacity freely and align output with its energy diversification plans.
Hegseth tells Asian allies China cannot impose hegemony in region
US Defense Secretary Pete Hegseth told Asian allies at the Shangri-La Dialogue in Singapore that China cannot impose hegemony on US partners in the region. The remarks frame Washington's Indo-Pacific posture and request for greater allied 'burden-sharing'.